Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) was down 7.8% on Thursday . The stock traded as low as $19.80 and last traded at $20.00. Approximately 528,821 shares traded hands during trading, an increase of 144% from the average daily volume of 216,627 shares. The stock had previously closed at $21.69.
Several equities research analysts recently weighed in on DCPH shares. Cantor Fitzgerald started coverage on Deciphera Pharmaceuticals in a report on Thursday, September 6th. They set a “buy” rating and a $53.00 price objective on the stock. Canaccord Genuity set a $55.00 price objective on Deciphera Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 13th. Zacks Investment Research raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Tuesday, July 24th. Guggenheim started coverage on Deciphera Pharmaceuticals in a report on Monday, September 17th. They set a “buy” rating on the stock. Finally, ValuEngine raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $45.44.
The firm has a market capitalization of $816.87 million, a P/E ratio of -6.69 and a beta of 3.79. The company has a quick ratio of 18.44, a current ratio of 18.44 and a debt-to-equity ratio of 0.05.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.65). As a group, equities research analysts predict that Deciphera Pharmaceuticals Inc will post -2.61 EPS for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE lifted its holdings in Deciphera Pharmaceuticals by 316.1% during the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after buying an additional 1,982 shares during the period. Trexquant Investment LP acquired a new position in Deciphera Pharmaceuticals during the 2nd quarter worth about $203,000. Rhumbline Advisers acquired a new position in Deciphera Pharmaceuticals during the 2nd quarter worth about $301,000. Highland Capital Management LP acquired a new position in Deciphera Pharmaceuticals during the 2nd quarter worth about $394,000. Finally, Wells Fargo & Company MN lifted its holdings in Deciphera Pharmaceuticals by 187.1% during the 3rd quarter. Wells Fargo & Company MN now owns 12,440 shares of the company’s stock worth $482,000 after buying an additional 8,107 shares during the period. 53.52% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Deciphera Pharmaceuticals (DCPH) Shares Down 7.8%” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/11/10/deciphera-pharmaceuticals-dcph-shares-down-7-8.html.
About Deciphera Pharmaceuticals (NASDAQ:DCPH)
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
See Also: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.